Our recent methodology for identifying novel, stabilized Schiff base–bound MR1 ligands at the cell surface via crosslinking mass spectrometry (49) will hopefully aid the discovery of new, natural MR1 ligands, including those recognized by CAITs and other cancer-activated MR1-restricted T cells. The gene discussed is MR1; the disease is cancer.